Research ArticleClinical Investigation
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer
Journal of Nuclear Medicine February 2023, 64 (2) 252-259; DOI: https://doi.org/10.2967/jnumed.122.264383
Esben Andreas Carlsen
1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Mathias Loft
1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Annika Loft
1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Dorota Czyzewska
1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Mikkel Andreassen
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
3Department of Clinical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Seppo W. Langer
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
4Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
5Department Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; and
Ulrich Knigge
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
3Department of Clinical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
6Department of Surgical Gastroenterology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Andreas Kjaer
1Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital, Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
2ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue 2
February 1, 2023
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer
Journal of Nuclear Medicine Feb 2023, 64 (2) 252-259; DOI: 10.2967/jnumed.122.264383
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer
Journal of Nuclear Medicine Feb 2023, 64 (2) 252-259; DOI: 10.2967/jnumed.122.264383